Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade - simplywall.st

AI-generated analysis

📈 Charles River Laboratories International (CRL) recently received a Morgan Stanley upgrade and announced a collaboration with Eli Lilly's AI drug discovery platform, TuneLab.

📊 The stock has shown recent momentum with a 15.41% return over the past 30 days and a 25.47% one-year total shareholder return.

💰 A community analysis pegs CRL's fair value at $313.61, suggesting the current price of $185 represents a 41% undervaluation opportunity.

🤝 The company is pursuing an acquisition of K.F. (Cambodia) in January 2026 to expand its research ecosystem.

⚠️ Simply Wall St's internal DCF model contradicts the bullish view, valuing the stock at $76.70 based on future cash flow projections.

🐒 Key risks include potential delays or failures in the Cambodia acquisition and stricter regulations affecting primate research capacity.

Bullish Signals
  • Morgan Stanley has upgraded Charles River Laboratories International, signaling increased institutional confidence in the company's prospects.
  • A new collaboration with Eli Lilly's AI platform, TuneLab, is expected to enhance drug discovery capabilities and potentially drive future revenue growth.
  • The stock has delivered strong short-term performance with a 15.41% gain over the last month and a 25.47% total return over the past year.
  • Analyst consensus fair value estimates suggest the stock is trading significantly below its perceived worth, creating a potential buying opportunity.
Risk Factors
  • Simply Wall St's internal Discounted Cash Flow (DCF) model values the company at $76.70, implying the current market price of $185 may be overvalued.
  • Tighter regulatory environments regarding primate research could constrain Charles River Laboratories International's core research capacity and revenue streams.
Full Analysis
Charles River Laboratories International (CRL) is highlighted by Simply Wall St as potentially undervalued following a Morgan Stanley upgrade and a strategic collaboration with Eli Lilly's AI drug discovery platform, TuneLab. The article notes that CRL shares have gained momentum recently, posting a 15.41% return over the past 30 days and a 25.47% total shareholder return over the last year, though longer-term returns remain weaker. The publication presents two conflicting valuation narratives for the company. A community-driven analysis suggests a fair value of $313.61, implying the stock is undervalued by approximately 41% relative to its recent closing price of $185. This bullish view relies on assumptions of rising margins and accelerating earnings driven by the new AI partnership and an acquisition of K.F. (Cambodia) scheduled for January 2026. Conversely, Simply Wall St's internal SWS Discounted Cash Flow (DCF) model calculates a future cash flow value of $76.70, suggesting the current market price is actually overvalued. The article concludes by outlining key risks to the bullish thesis, including potential setbacks to the Cambodia acquisition and tighter regulations on primate research that could constrain the company's capacity.